
HRMY Stock Forecast & Price Target
HRMY Analyst Ratings
Bulls say
Harmony Biosciences Hldgs is well-positioned for future success with its innovative therapies for rare neurological disorders and its strong product WAKIX (pitolisant) already showing promising results. The company's extended half-life compared to competitors, strong safety profile, and potential for a differentiated label in narcolepsy highlight its strong potential. With preliminary 2Q26 revenues exceeding expectations and continued future catalysts, including a potential blockbuster status and a strong IP portfolio, Harmony Biosciences Hldgs presents a buying opportunity for investors. However, potential risks include competition and clinical trial outcomes.
Bears say
Harmony Biosciences Hldgs is currently trading higher, likely in response to the positive Phase 1 data on its drug candidate BP-205, which has potential as a potent OX2R molecule for multiple CNS indications. However, there are some concerns regarding the growth outlook for its main product Wakix, as well as potential competition from generic versions. Additionally, the company's orphan drug pipeline adds potential growth drivers, but there is still uncertainty around their success.
This aggregate rating is based on analysts' research of Harmony Biosciences Holdings and is not a guaranteed prediction by Public.com or investment advice.
HRMY Analyst Forecast & Price Prediction
Start investing in HRMY
Order type
Buy in
Order amount
Est. shares
0 shares